SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios latest earnings beat and raised full-year outlook were overshadowed by softer fourth-quarter organic-growth guidance, signaling a slowdown from the prior quarter. Traders are debating whether the selloff is an overreaction to the outlook or a justified repricing for decelerating growth and weaker customer expansion.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Investors are focused on Revolution Medicines upcoming quarterly update for the first full quarter of RASONQUE sales, especially whether new-patient starts show an accelerating launch ramp. Traders are weighing the drugs clinical success and broader pipeline against questions about commercial uptake, competition, and the stocks recent volatility.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is pulling back alongside weakness in cybersecurity and technology stocks, while traders also cite put-heavy options activity and circulate unverified claims of a DHS-related data exposure. The planned S&P 500 inclusion is a bullish counterpoint, but discussion questions whether index-related demand can offset sector pressure and valuation concerns.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradynes strong quarterly results are being overshadowed by a selloff as traders question its next-quarter outlook and cite margin pressure, product mix, and competition. Bulls point to AI-driven chip-testing demand, while bearish comments and put-heavy options positioning reflect concern that the growth outlook may not justify the stocks valuation.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rally and elevated trading activity have sparked bullish calls for a breakout, while traders debate whether it can clear resistance or will pull back. Supporters point to Chainlinks institutional and tokenization integrations, while skeptics question whether network adoption will translate into value for the LINK token.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS and prompted a sharp selloff. Traders disagree over the threat, weighing Voceryqs potential to reduce surgeries against PAPZIMEOSs commercial head start and full-approval status, while questioning Inovios reimbursement and launch execution.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its relatively steady price action and repeated technical-trading discussion, with many posts describing consolidation or a pullback after a rally. Traders are split between viewing the dip as a healthy pause with long-term strength and worrying that TRX is lagging or could fall further.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

TWST is drawing attention after a sharp, high-volume selloff following a steep rally, with traders linking the move to profit-taking and a broader pullback across speculative genomics and biotech stocks rather than a clearly identified company-specific catalyst. The community is split between bearish concerns about valuation and insider selling and bullish claims of short pressure or market manipulation.

Onyxcoin (XCN) is a cryptocurrency launched in 2021and operates on the Ethereum platform. Onyxcoin has a current supply of 53,402,422,627.32441369 with 40,400,796,729.46127832 in circulation. The last known price of Onyxcoin is 0.00378971 USD and is down -1.54 over the last 24 hours. It is currently trading on 205 active market(s) with $5,616,621.35 traded over the last 24 hours. More information can be found at https://onyx.org.

Onyxcoin

Onyxs ecosystem expansionparticularly discussion of a Robinhood Chain testnet bridge involving ETH and tokenized TSLAis drawing attention, with some traders seeing potential in tokenized assets and payments. Others focus on XCNs weakness and volatile spikes, questioning whether the developments are translating into sustained demand.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP memecoins steep decline from its launch highs and reported losses among retail holders dominate discussion, with many traders calling it a pump-and-dump while others argue for accumulating or expect a rebound. The debate is closely tied to backlash over Trump and his familys crypto ventures, though claims of a deliberate scam remain traders opinions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Equity

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.


Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

AEON Biopharma Inc. - Ordinary Shares - Class A

Bearish Sentiment

Mineralys Therapeutics Inc. (195% increase in followers)Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone.Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for cardiorenal conditions.Last month, Mineralys reported positive topline results from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled and resistant hypertension. Both studies met their primary efficacy endpoints with statistical significance.&nbsp;In February, Mineralys reported a smaller-than-expected quarterly loss and disclosed that cash, cash equivalents, and investments stood at $198.2 million as of Dec. 31, 2024, which it expects to support clinical studies and corporate operations through the first quarter of 2026.The stock has gained over 28% year-to-date, with short interest at 4.5%, according to Koyfin.Sana Biotechnology Inc. (177% increase in followers)Sana focuses on developing engineered cell therapies to repair or replace damaged or missing cells, as well as control and modify genes.This year, the company has attracted significant investor interest following a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes. In January, it demonstrated that its hypoimmune edits enabled islet cell transplants to survive without immunosuppression, a result that drew praise from analysts.Last month, Citizens JMP upgraded Sana's stock, citing the validation of its Hypoimmune platform in type 1 diabetes, upcoming SC291 data in autoimmune diseases expected in 2025, and a strong cash position of $152.5 million. The firm considers Sana undervalued.Jefferies notes that Sana has three assets in development across different disease areas and projects peak adjusted revenues of $2.8 billion.Sana's stock is up just over 3% year-to-date, with short interest at 17.7%, according to Koyfin.Aeon Biopharma Inc. (132% increase in followers)This is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex for treating neurological conditions. Evolus markets the same botulinum toxin complex cosmetically under the name Jeuveau.ABP-450 is already approved as a biosimilar in Mexico and India. Aeon holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select international markets.The stock gained attention this year following a 1-for-72 reverse stock split in March to maintain NYSE American's minimum share price requirement.Last month, Aeon announced that CEO Marc Forth would step down on April 4 to pursue another opportunity, with Chairman Jost Fischer stepping in as interim CEO.Aeon's stock has plunged over 98% year-to-date, with short interest last at 1.7%, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys Therapeutics Inc

Sana Biotechnology Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.274
Prev Close	$0.294
Open	$0.2844
Dividend Yield	0.00%
50-Day Moving Average	$0.2601
Beta	0.67
Avg. Volume	17.64M
PE Ratio	-0.07

52-Week High	$1.45
52-Week Low	$0.1772
Market Capitalization	$16.19M
EPS (Annual)	-$3.95
Price to Book	-0.47
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

AEON Fundamentals